NASDAQ:EDGE - Edge Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.4050 -0.01 (-2.41 %) (As of 02/22/2019 04:00 PM ET)Previous Close$0.4050Today's Range$0.39 - $0.4352-Week Range$0.28 - $17.77Volume184,397 shsAverage Volume316,449 shsMarket Capitalization$12.69 millionP/E RatioN/ADividend YieldN/ABeta3.73 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey. Receive EDGE News and Ratings via Email Sign-up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDGE Previous Symbol CUSIPN/A CIK1472091 Webwww.edgetherapeutics.com Phone800-208-3343Debt Debt-to-Equity RatioN/A Current Ratio5.55 Quick Ratio5.55Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book0.20Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-50,850,000.00 Net MarginsN/A Return on Equity-77.72% Return on Assets-52.26%Miscellaneous Employees14 Outstanding Shares31,330,000Market Cap$12.69 million Next Earnings Date5/7/2019 (Estimated) OptionableOptionable Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions What is Edge Therapeutics' stock symbol? Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE." How were Edge Therapeutics' earnings last quarter? Edge Therapeutics Inc (NASDAQ:EDGE) released its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.16. View Edge Therapeutics' Earnings History. When is Edge Therapeutics' next earnings date? Edge Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Edge Therapeutics. What price target have analysts set for EDGE? 2 brokerages have issued 1-year price targets for Edge Therapeutics' stock. Their predictions range from $17.00 to $17.00. On average, they expect Edge Therapeutics' stock price to reach $17.00 in the next year. This suggests a possible upside of 4,097.5% from the stock's current price. View Analyst Price Targets for Edge Therapeutics. What is the consensus analysts' recommendation for Edge Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edge Therapeutics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Edge Therapeutics. Has Edge Therapeutics been receiving favorable news coverage? Headlines about EDGE stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Edge Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Edge Therapeutics' key competitors? Some companies that are related to Edge Therapeutics include Vascular Biogenics (VBLT), Sienna Biopharmaceuticals (SNNA), Clearside Biomedical (CLSD), Selecta Biosciences (SELB), Bellerophon Therapeutics (BLPH), Novus Therapeutics (NVUS), Ovid Therapeutics (OVID), BIOLINERX LTD/S (BLRX), DiaMedica Therapeutics (DMCAF), PLx Pharma (PLXP), Vistagen Therapeutics (VTGN), Diamedica Therapeuti (DMAC), Achaogen (AKAO), Celsion (CLSN) and Helix Biopharma (HBPCF). What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), McEwen Mining (MUX), Cerecor (CERC), Crispr Therapeutics (CRSP), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), Paratek Pharmaceuticals (PRTK), Omeros (OMER), Iovance Biotherapeutics (IOVA) and Viking Therapeutics (VKTX). Who are Edge Therapeutics' key executives? Edge Therapeutics' management team includes the folowing people: Mr. Brian A. Leuthner, Co-Founder, CEO, Pres & Director (Age 54)Dr. R. Loch MacDonald, Co-Founder, Chief Scientific Officer & Director (Age 57)Mr. Andrew Saik, Chief Financial Officer (Age 50)Mr. W. Bradford Middlekauff, Sr. VP, Gen. Counsel & Sec. (Age 57)Mr. William Shatynski, Sr. Director of Financial Reporting & Controller Who are Edge Therapeutics' major shareholders? Edge Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Two Sigma Investments LP (0.76%) and Bronfman E.L. Rothschild L.P. (0.32%). Company insiders that own Edge Therapeutics stock include Albert N Marchio II, Brian A Leuthner, James J Loughlin and R Loch Macdonald. View Institutional Ownership Trends for Edge Therapeutics. Which institutional investors are selling Edge Therapeutics stock? EDGE stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP. Company insiders that have sold Edge Therapeutics company stock in the last year include Brian A Leuthner and R Loch Macdonald. View Insider Buying and Selling for Edge Therapeutics. Which institutional investors are buying Edge Therapeutics stock? EDGE stock was bought by a variety of institutional investors in the last quarter, including Bronfman E.L. Rothschild L.P.. View Insider Buying and Selling for Edge Therapeutics. How do I buy shares of Edge Therapeutics? Shares of EDGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Edge Therapeutics' stock price today? One share of EDGE stock can currently be purchased for approximately $0.4050. How big of a company is Edge Therapeutics? Edge Therapeutics has a market capitalization of $12.69 million. Edge Therapeutics employs 14 workers across the globe. What is Edge Therapeutics' official website? The official website for Edge Therapeutics is http://www.edgetherapeutics.com. How can I contact Edge Therapeutics? Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected] MarketBeat Community Rating for Edge Therapeutics (NASDAQ EDGE)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 135 (Vote Outperform)Underperform Votes: 142 (Vote Underperform)Total Votes: 277MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe EDGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDGE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2019 by MarketBeat.com StaffFeatured Article: What are retained earnings?